Celecoxib for the treatment of musculoskeletal arthritis

Krasselt, Marco; Baerwald, Christoph

doi:10.1080/14656566.2019.1645123

Cited by 58 publications

(33 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, nonsteroidal anti-inflammatory drugs (NSAIDs) are prescribed for patients with OA; however, these can cause various adverse effects owing to the toxicity of this class of drugs [ 33 , 34 , 35 ]. A representative NSAID for patients with OA is celecoxib, a selective Cox2 inhibitor, which is prescribed to control inflammation [ 36 , 37 , 38 ].…”

Section: Discussionmentioning

confidence: 99%

Obtusifolin, an Anthraquinone Extracted from Senna obtusifolia (L.) H.S.Irwin & Barneby, Reduces Inflammation in a Mouse Osteoarthritis Model

et al. 2021

View full text Add to dashboard Cite

Osteoarthritis (OA) is an age-related degenerative disease that causes cartilage dysfunction and inflammation. Obtusifolin, an anthraquinone extracted from Senna obtusifolia (L.) H.S.Irwin & Barneby seeds, has anti-inflammatory functions; it could be used as a drug component to relieve OA symptoms. In this study, we investigated the effects of obtusifolin on OA inflammation. In vitro, interleukin (IL)-1β (1 ng/mL)-treated mouse chondrocytes were co-treated with obtusifolin at different concentrations. The expression of matrix metalloproteinase (Mmp) 3, Mmp13, cyclooxygenase 2 (Cox2), and signaling proteins was measured by polymerase chain reaction and Western blotting; collagenase activity and the PGE2 level were also determined. In vivo, OA-induced C57BL/6 mice were administered obtusifolin, and their cartilage was stained with Safranin O to observe damage. Obtusifolin inhibited Mmp3, Mmp13, and Cox2 expression to levels similar to or more than those after treatment with celecoxib. Additionally, obtusifolin decreased collagenase activity and the PGE2 level. Furthermore, obtusifolin regulated OA via the NF-κB signaling pathway. In surgically induced OA mouse models, the cartilage destruction decreased when obtusifolin was administered orally. Taken together, our results show that obtusifolin effectively reduces cartilage damage via the regulation of MMPs and Cox2 expression. Hence, we suggest that obtusifolin could be a component of another OA symptom reliever.

show abstract

Section: Discussionmentioning

confidence: 99%

Obtusifolin, an Anthraquinone Extracted from Senna obtusifolia (L.) H.S.Irwin & Barneby, Reduces Inflammation in a Mouse Osteoarthritis Model

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Some studies have demonstrated that piperlongumine relieves RA through expansion of myeloid-derived suppressor cells (MDSCs) and the inhibition of the Th17 response and activation of fibroblast-like synoviocytes (FLS)43 represses dendritic cell maturation by decreasing production of reactive oxygen species,44 and suppresses proliferation, migration and invasion of FLS45 via animal model and patient samples. Celecoxib has been approved to treat RA and osteoarthritis (OA);46,47 it, combined with Cilostazol, impedes proinflammatory factors in FLS of RA patients 48. These results may provide more favorable evidence for the clinical use of these drugs.…”

Section: Discussionmentioning

confidence: 99%

<p>Individualized Drug Repositioning For Rheumatoid Arthritis Using Weighted Kolmogorov–Smirnov Algorithm</p>

Tian

et al. 2019

PGPM

View full text Add to dashboard Cite

BackgroundExisting drugs are far from enough for investigators and patients to administrate the therapy of rheumatoid arthritis. Drug repositioning has drawn broad attention by reusing marketed drugs and clinical candidates for new uses.PurposeThis study attempted to predict candidate drugs for rheumatoid arthritis treatment by mining the similarities of pathway aberrance induced by disease and various drugs, on a personalized or customized basis.MethodsWe firstly measured the individualized pathway aberrance induced by rheumatoid arthritis based on the microarray data and various drugs from CMap database, respectively. Then, the similarities of pathway aberrances between RA and various drugs were calculated using a Kolmogorov–Smirnov weighted enrichment score algorithm.ResultsUsing this method, we identified 4 crucial pathways involved in rheumatoid arthritis development and predicted 9 underlying candidate drugs for rheumatoid arthritis treatment. Some candidates with current indications to treat other diseases might be repurposed to treat rheumatoid arthritis and complement the drug group for rheumatoid arthritis.ConclusionThis study predicts candidate drugs for rheumatoid arthritis treatment through mining the similarities of pathway aberrance induced by disease and various drugs, on a personalized or customized basis. Our framework will provide novel insights in personalized drug discovery for rheumatoid arthritis and contribute to the future application of custom therapeutic decisions.

show abstract

“…It is a member of a non-steroidal anti-inflammatory drug (NSAID) class that has significantly less severe side effects in the gastrointestinal tract, such as gastric ulceration, compared to conventional non-selective NSAIDs. Although long-term treatment may increase the risk of adverse side effects in the cardiovascular system, celecoxib has cancer [1][2][3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Development of a Unified Reversed-Phase HPLC Method for Efficient Determination of EP and USP Process-Related Impurities in Celecoxib Using Analytical Quality by Design Principles

2020

View full text Add to dashboard Cite

This article presents the development of a reversed-phase (RP) high-performance liquid chromatographic (HPLC) method for determination of process-related impurities in a celecoxib drug substance following Analytical Quality by Design (AQbD) principles. The method from European Pharmacopeia (EP) for celecoxib drug substance does not sufficiently separate celecoxib from its EP impurity B because the system suitability criterion is not achieved (resolution NLT 1.8). The same issue was observed with the proposed method from United States Pharmacopeia (USP) for celecoxib capsules, where EP impurity A elutes under the main peak. A new HPLC method was developed that eliminates the disadvantages of the two pharmacopeial methods and is capable of efficiently separating and determining all seven impurities listed in EP and the proposed USP monographs. The development of a new HPLC method started with method scouting, in which various C18 and phenyl stationary phases were tested. Improved selectivity was obtained only with a chiral stationary phase. An immobilized Chiralpak IA-3 column used in RP mode turned out to be the most appropriate for method optimization. The ratio of acetonitrile in the mobile phase, flow rate, and column temperature were recognized as critical method parameters (CMPs) and were further investigated using a central composite face response-surface design. A multiple linear regression (MLR) method was applied to fit the mathematical models on the experimental data to determine factor–response relationships. The models created show adequate fit and good prediction abilities. The Monte Carlo simulation method was used to establish the design space. The method developed was verified in terms of precision, sensitivity, accuracy, and linearity, and the results showed that the new method is suitable for determination of seven process-related impurities of celecoxib.

show abstract

Celecoxib for the treatment of musculoskeletal arthritis

Cited by 58 publications

References 75 publications

Obtusifolin, an Anthraquinone Extracted from Senna obtusifolia (L.) H.S.Irwin & Barneby, Reduces Inflammation in a Mouse Osteoarthritis Model

Obtusifolin, an Anthraquinone Extracted from Senna obtusifolia (L.) H.S.Irwin & Barneby, Reduces Inflammation in a Mouse Osteoarthritis Model

<p>Individualized Drug Repositioning For Rheumatoid Arthritis Using Weighted Kolmogorov–Smirnov Algorithm</p>

Development of a Unified Reversed-Phase HPLC Method for Efficient Determination of EP and USP Process-Related Impurities in Celecoxib Using Analytical Quality by Design Principles

Contact Info

Product

Resources

About